lowed by a maintenance infusion over the remainder of the scanning session (a total of 90 min), using a computer-operated pump (Arcomed, Syramed SP600, Regensdorf, Switzerland). Dynamic emission scanning (41 frames of 0-6,000 s; 100-min scan; framed as 4 × 15, 8 × 30, 9 × 60, 2 × 180, 4 × 300, 6 × 200, and 8 × 300 s) was initiated with injection of the [ 11 C]raclopride bolus. The regional DA D2/3 nondisplaceable binding potential (BP ND ) was measured in the resting state, in all participants, 1 week before the reward study.
C]raclopride ΔBP indicated the percentage of [
11 C]raclopride displacement by endogenously released DA. Greater negative values indicate greater [ 11 C]raclopride displacement. One-sample t tests were used to test the significance of ΔBP in each region and each group. The findings were corrected for multiple comparisons using Bonferroni correction (significance threshold set at α = 0.005) for 2-tailed p values. The a priori hypothesis was tested using 1-way ANOVA with group as a factor for the ΔBP obtained in the striatal ROIs. Since age is known to influence D2/D3 receptor BP, this factor was included as covariate in the analysis. Significant group effects indicated by the ANOVA were further tested using the Gabriel post hoc test.
In additional analyses with the covariates severity of depressive symptoms, FMS duration, and antidepressant medication, no correlations were found with BP ND in any striatal regions.
Dear Editor,
We herein report results of our pilot study using bolus-plusinfusion [ 11 C]raclopride positron emission tomography (PET) scanning to assess endogenous dopamine (DA) release associated with unpredictable monetary rewards in patients with fibromyalgia syndrome (FMS) and healthy controls. The aim of this project was to investigate whether FMS was associated with a dysfunction of the central reward system. Twenty-four women with FMS, based on the American College of Rheumatology classification criteria for FMS, and 17 agematched healthy women were included in the study. Eleven of the patients with FMS met the DSM-V criteria for major depressive disorder (MDD) [1] (current and past depressive episode). A slot machine task validated by Martin-Soelch et al. [2] , which has been shown to reliably induce equilibrium and task-related changes in raclopride binding, was used to measure endogenous DA release in response to unpredictable rewards. PET examinations were performed on a full ring PET/computerized tomography (CT) scanner with a 15.3-cm axial field of view in 3-dimensional mode (Discovery DSTX, GE Healthcare, Waukesha, WI, USA), at the Department of Nuclear Medicine, University Hospital Zurich, Switzerland. The emission data were corrected for attenuation, scatter, random, and dead time using the corresponding CT (120 kV/80 mA), and reconstructed using filtered back projection. [
11 C]Raclopride (415 ± 30 MBq) was administered as an initial bolus over 60 s, according to the protocol described by Watabe et al. We found unexpectedly significant reductions in D2/D3 receptor BPs in the reward versus the control condition in the right nucleus accumbens and caudate nucleus in both FMS groups compared to controls, which may indicate increased DA release ( Fig. 1 ) . The effects in the right nucleus accumbens were more prominent in patients with FMS and comorbid depression (41.1%) compared to healthy controls (23.3%; p < 0.01). Reductions in the right caudate nucleus of patients with FMS were also greater in patients with comorbid depression (24.6%) compared to patients without depression (13.4%; p < 0.02). The differences in percentage displacement observed between groups suggest differences in the neural processing of rewards as measured by the DA release associated with unpredictable rewards. Our findings in patients with FMS and MDD are not in line with previous attempts at elucidating the striatal response to reward in individuals with MDD [5, 6] . The finding that the DA response to rewarding stimuli increased in patients with FMS and comorbid depression is novel. One possible explanation for the accentuated DA reaction in our patients with FMS may be an upregulation of the mesolimbic DA system, which occurs due to underactivation of the striatal and prefrontal DA projections to the mesolimbic DA system. Another possibility is that chronic exposure to stress from persistent pain may have affected the DA response in our patients with FMS; recent animal studies have provided evidence that repeated exposure to stress can affect both tonic and phasic DA release in the nucleus accumbens and medial prefrontal cortex [7] .
Our findings extend previous research on chronic pain-related impairments in reward processing [8, 9] and show that patients with FMS and depression can be distinguished from those without depression on a neurobiological level. Furthermore, the finding that FMS patients with and without MDD exhibited different DA release patterns has important implications for identifying distinct properties of the neural circuitry underlying FMS with and without comorbid MDD. Customized treatment strategies according to pathophysiological features defining FMS subgroups should be considered. Multidisciplinary pharmacologic and cognitive behavioral approaches are currently viewed as the most effective treatments. Drug selection should target the most prominent comorbid symptoms, e.g. amitriptyline or pregabalin for those with sleep disturbances, duloxetine for those with MDD [10] . Moreover, the present findings suggest that pharmacologic and psychotherapeutic interventions to restore DA regulation may be therapeutically beneficial in patients with FMS. 
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